SGMT Stock Overview
A clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Sagimet Biosciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.72 |
| 52 Week High | US$20.71 |
| 52 Week Low | US$2.39 |
| Beta | 0 |
| 1 Month Change | -17.05% |
| 3 Month Change | 51.28% |
| 1 Year Change | -12.92% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -70.41% |
Recent News & Updates
Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans
Dec 15
Sagimet: More Than Just A MASH Drug Development Biotech
Nov 14Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat
Oct 18Recent updates
Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans
Dec 15Sagimet: More Than Just A MASH Drug Development Biotech
Nov 14Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat
Oct 18Sagimet Biosciences' Denifanstat Remains A Strong Buy Despite Eli Lilly's Tirzepatide
Jul 31Companies Like Sagimet Biosciences (NASDAQ:SGMT) Are In A Position To Invest In Growth
May 31Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity
Apr 26Sagimet: Additional Upside Possible After Latest NASH Data Release
Jan 24Shareholder Returns
| SGMT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.0% | 0.7% | 0.6% |
| 1Y | -12.9% | -3.4% | 23.7% |
Return vs Industry: SGMT underperformed the US Biotechs industry which returned -3.4% over the past year.
Return vs Market: SGMT underperformed the US Market which returned 23.7% over the past year.
Price Volatility
| SGMT volatility | |
|---|---|
| SGMT Average Weekly Movement | 16.5% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SGMT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SGMT's weekly volatility has decreased from 29% to 16% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 9 | Dave Happel | www.sagimet.com |
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company’s lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs.
Sagimet Biosciences Inc. Fundamentals Summary
| SGMT fundamental statistics | |
|---|---|
| Market cap | US$159.05m |
| Earnings (TTM) | -US$37.52m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.1x
P/E RatioIs SGMT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SGMT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$37.52m |
| Earnings | -US$37.52m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.17 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SGMT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 23:44 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sagimet Biosciences Inc. is covered by 8 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrea Tan | Goldman Sachs |
| Andrea Newkirk | Goldman Sachs |
| Antonio Arce | H.C. Wainwright & Co. |